Purpose: To evaluate the safety and efficiency of adalimumab in children with severe refractory JIA with primary inefficiency, partial effect or loss of the effectiveness of other biologicals. Patients and methods: The article presents the results of the retrospective observational study of the efficacy and safety of adalimumab in 68 patients aged 10 (3, 17) years with various embodiments of JIA , with the primary inefficiency or partial or loss of the effectiveness of other biologicals. JIA diagnosis established on the basis of criteria ILAR (International League of Associations for Rheumatology). Results: Efficacy was assessed during 1 year in 68 and 2 years - in 56 patients . At the 24th week we observed the improvement by criteria AKR in 100 , 91 and 74 % of patients , respectively, and at the 52 th week - in 100 , 96 and 90 % , respectively. Inactive disease status was recorded in 55.8, 66,1 and 98.2 % of study participants after 6 months, 1 and 2 years, respectively. Remission was achieved in 55.8 and 96.4 % of patients after 1 and 2 years of observation, respectively. Conclusions: Adalimumab was effective and well tolerated by patients with primary inefficiency, partial and loss of efficiency of other biologicals. In clinical practice, patients with non-systemic JIA transition to the second TNF-α blocker can restore the biological effect of the first drug without increasing the frequency of infectious AEs.
EFFICACY AND SAFETY OF ANTI-TNFα HUMAN MONOCLONAL ANTIBODIES IN CHILDREN WITH JUVENILE IDIOPATHIC ARTHRITIS AND SECONDARY RESISTANCE TO OTHER GENETICALLY ENGINEERED BIOLOGICAL AGENTS